Renhuang Pharmaceuticals, Inc. (OTCBB: RHGP), a leading provider of natural health care products in the People's Republic of China (PRC), filed its first 10K since it went public in September 2006 and announced its results for the transition period of May 1 to October 31, 2006.
Basic earnings per common share for the six month period were $0.125 per share. Revenues for the six month period from May 1 to October 31, 2006 remained strong, reaching $12.25 million compared to $11.72 million for the same period of last year. Overall, the Company is very optimistic about growing its earnings and revenues over time. With several new products recently launched and its traditional products in strong demand, the Company is confident that earnings and revenues will grow continuously.
"We are very pleased to see our earnings grow significantly year over year, with a net income of $4.4 million generated in this first six month period since we became a public company," said Mr. Li Shaoming. "In the light of the current results, we believe in a continued growth and profitability given our highly sought after products, strong R&D program, superior manufacturing capability, and large distribution network. We expect to continue to deliver high growth in our business and we are committed to looking for every opportunity to create value for our shareholders. For the fiscal year 2007 we expect revenues to be between $35 to $40 million and net profits to be between $10 to $12 million."
Other stocks highlighted include NVIDIA Corporation (NASDAQ: NVDA): Hot Stocks List, up 1% on 1 million shares, Daktronics, Inc. (NASDAQ: DAKT): Hot Stocks List, down 1% on 2 million shares.
"With energy prices falling, consumers are getting immediate inflation relief at the pump. A sustained drop in energy prices could also take price pressure off airlines, shippers and other transportation companies that have been passing along their higher fuel costs to consumers." More is available at: http://www.thesubway.com.
TheSUBWAY.com's Daily Stock Updates:
TheSUBWAY.com, a leader in corporate communications and finance, highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long term" view of any of the companies listed. For more go to http://www.thesubway.com.
All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate , and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRG has been compensated fifty five thousand shares for RHGP. CRG has also purchased five thousand shares in the open market. CRG intends to sell its shares. CRG has sold approximately zero RHGP shares to date. CRG may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRG's affiliates, officers, directors and employees intend to buy and sell additional shares in any company mentioned within and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
